XM does not provide services to residents of the United States of America.
A
A

AllianzAG

News

Novo Nordisk's weight-loss drug Wegovy's price and availability

FACTBOX-Novo Nordisk's weight-loss drug Wegovy's price and availability Adds Brazil, Italy, France, updates currency conversions Nov 20 (Reuters) - Novo Nordisk NOVOb.CO has launched its wildly popular weight-loss drug Wegovy in more than 15 countries since 2021 at prices ranging from $200 to almost $2,000 a month, as Eli Lilly LLY.N also began selling its rival drug in Europe and the U.S.
A

Metzler sees challenging start to 2025 for German stocks amid economic, political risks

BUZZ-Metzler sees challenging start to 2025 for German stocks amid economic, political risks ** Metzler Capital Markets sees challenging starting conditions into 2025 for Germany, deepened by Chancellor Olaf Scholz's government collapse earlier this month, and forecasts economic growth to accelerate only moderately in 2025 after a potential stagnation or slight decline this year ** The brokerage flags risks to German exports from tariff hike plans by incoming U.S.
A
C
D
R
S
A
G

Novo Nordisk's weight-loss drug Wegovy's price and availability

FACTBOX-Novo Nordisk's weight-loss drug Wegovy's price and availability Updates China Nov 19 (Reuters) - Novo Nordisk NOVOb.CO has launched its wildly popular weight-loss drug Wegovy in more than 10 countries since 2021 at prices ranging from $200 to almost $2,000 a month, as Eli Lilly LLY.N also began selling its rival drug in Europe and the U .S . The Danish drugmaker is working to convince European governments and insurers to reimburse the drug, seeking to position it as more than a lifestyle
A

Allianz SE, Just Group, Zurich Insurance

EUROPE RESEARCH ROUNDUP-Allianz SE, Just Group, Zurich Insurance Nov 19 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Allianz SE, Just Group and Zurich Insurance Group, on Tuesday. HIGHLIGHTS * Allianz SE ALVG.DE : HSBC raises target price to EUR 350 from EUR 335 * Bayer AG BAYGn.DE : Berenberg cuts target price to EUR 22 from EUR 28 * Just Group JUSTJ.L : JP Morgan raises target price to 200p from 190p * Young & Co'S Brewery Plc
3
A
A
A
B
C
D
E
H
H
M
R
S
S
S
S
S
V
A
P
A
B
Z

4Imprint, Admiral Group, Prudential

EUROPE RESEARCH ROUNDUP-4Imprint, Admiral Group, Prudential Nov 18 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including 4Imprint, Admiral Group and Prudential, on Monday. HIGHLIGHTS * 4Imprint FOUR.L : HSBC cuts target price to 5830p from 6370p * Admiral Group Plc ADML.L : Barclays raises target price to 3326p from 3157p * Intermediate Capital Group Plc ICGIN.L : Citigroup raises PT to 2660p from 2610p * Prudential Plc PRU.L : Barclays
3
A
A
A
A
A
B
B
B
D
E
G
H
H
A
A
A
A
A
B
D
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.